Affordable Access

Publisher Website

Simultaneous determination of 16 anti-HIV drugs in human plasma by high-performance liquid chromatography

Journal of Chromatography B
Publication Date
DOI: 10.1016/j.jchromb.2005.12.016
  • Hiv Protease Inhibitors
  • Hiv Nucleoside Reverse Transcriptase Inhibitors
  • Hiv Non-Nucleoside Reverse Transcriptase Inhibitors
  • Hplc–Uv
  • Therapeutic Drug Monitoring
  • Medicine


Abstract Therapeutic drug monitoring (TDM) is pivotal to improve the management of HIV infection. Here, a HPLC–UV method has been developed to quantify simultaneously seven HIV protease inhibitors (amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir, and saquinavir; PIs), seven nucleoside reverse transcriptase inhibitors (abacavir, didanosine, emtricitabine, lamivudine, stavudine, zalcitabine, and zidovudine; NRTIs), and two non-nucleoside reverse transcriptase inhibitors (efavirenz and nevirapine; NNRTIs) in human plasma. The volume of the plasma sample was 600 μL. This method involved automated solid-phase extraction with Oasis HLB Cartridge 1 cc (divinylbenzene and N-vinylpyrrolidone) and evaporation in a water bath under nitrogen stream. The extracted samples were reconstituted with 100 μL methanol. Twenty microliters of these samples were injected into a HPLC–UV system, the analytes were eluted on an analytical C 18 Symmetry™ column (250 mm × 4.6 mm I.D.) with a particle size of 5 μm. The mobile phase (0.01 M KH 2PO 4 and acetonitrile) was delivered at 1.0 mL/min with linear gradient elution. The total run time for a single analysis was 35 min, the anti-HIV drugs were detected by UV at 240 and 260 nm. The calibration curves were linear up to 10 μg/mL. The absolute recovery ranged between 88 and 120%. The in vitro stability of anti-HIV drugs (0.005–10 μg/mL) in plasma has been studied at 24.0 °C. On these bases, a two to four analyte method has been tailored to the individual needs of the HIV-infected patient. The HPLC–UV method here reported has been validated and is currently applied to monitor PIs, NRTIs, and NNRTIs in plasma of HIV-infected patients. It allows to monitor the largest number of anti-HIV drugs simultaneously, appearing useful in a routine laboratory, and represents an essential step to elucidate the utility of a formal therapeutic drug monitoring for the optimal follow-up of HIV-infected patients.

There are no comments yet on this publication. Be the first to share your thoughts.


Seen <100 times

More articles like this

Simultaneous determination of 16 anti-HIV drugs in...

on Journal of Chromatography B Feb 02, 2006

Simultaneous determination of anticonvulsant drugs...

on Journal of chromatography Aug 09, 1985

The simultaneous determination of five anti-epilep...

on Methods and findings in experi... November 1984

Simultaneous determination of oral antidiabetic dr...

on Journal of Pharmaceutical and... Aug 05, 2014
More articles like this..